Reported 14 days ago
Novo Nordisk's CEO announced that the widely-used diabetes drug Ozempic will qualify for U.S. government price negotiations under the Inflation Reduction Act by 2027. This statement was made as he prepares to testify about the pricing of Ozempic and the weight-loss drug Wegovy before a Senate committee. The current list price for Ozempic is $935.77 per month, though actual consumer prices can vary based on insurance. Critics have pointed out the high cost of these medications, and Novo expects net prices for both drugs to continue decreasing.
Source: YAHOO